Form 4: LeonaBio Executive Acquires Stock Options

Mark Worthington, General Counsel and CCO of LeonaBio, Inc., acquired 300,000 stock options with an exercise price of $9.54.

Summary

• Mark Worthington, General Counsel and Chief Compliance Officer (CCO) of LeonaBio, Inc., has acquired 300,000 stock options.
• The options have an exercise price of $9.54 per share.
• These options are exercisable starting April 9, 2026, and expire on April 8, 2036.
• The underlying securities are 300,000 shares of LeonaBio's Common Stock.
• The options are subject to a vesting schedule, with shares vesting monthly over 48 months, contingent on continued employment.
• This transaction was reported on April 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard executive compensation mechanism rather than a significant strategic or financial development.

Positives

• Acquisition of stock options by a key executive can signal confidence in the company's future performance.
• The vesting schedule over 48 months aligns the executive's incentives with long-term company growth.

Risks

• The value of the stock options is directly tied to the future stock price of LeonaBio, Inc., which is subject to market volatility and company performance.
• Vesting is contingent on continued employment, meaning the executive could forfeit unvested options if they leave the company.

Future Outlook

The stock options are exercisable starting April 9, 2026, and vest over a 48-month period, indicating a long-term outlook for the executive's engagement and the company's potential growth.

Industry Context

StockSavvy.ai notes that the granting of stock options to key executives is a common practice in the biotechnology sector to attract and retain talent, aligning their financial interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The acquisition of options by management can be seen as a positive sign of commitment, but the ultimate impact depends on the company's stock performance.
• Employees: This transaction highlights standard executive compensation practices within the company.
• Management: The executive's financial success is now more directly tied to the company's stock performance.

Next Steps

• The executive will continue to vest in the stock options over the next 48 months, subject to continued employment.
• The options can be exercised by the executive from April 9, 2026, until their expiration on April 8, 2036.

Key Dates

Keywords

LeonaBio, LONA, Form 4, Stock Options, Insider Transaction, Executive Compensation, General Counsel, CCO, Beneficial Ownership